There should be quite a bit of news to follow over next few months. FDA (INAD) application, CSRIO collaboration, CPAT-01 trial update/result read out, DermaCann trial and possible distribution agreements.
I suspect things could heat up for CP1 in the coming months.
All IMO. DYOR
- Forums
- ASX - By Stock
- CP1
- Ann: Quarterly Report 30 June 2019
Ann: Quarterly Report 30 June 2019, page-12
-
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)